Welcome to our dedicated page for Smith & Nephew SEC filings (Ticker: SNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Smith & Nephew plc (SNN) regulatory disclosures filed with the U.S. Securities and Exchange Commission, primarily through Form 6-K current reports for foreign private issuers. These filings give investors structured insight into the company’s capital structure, strategy, acquisitions and transactions by senior management.
Smith & Nephew uses Form 6-K to report a range of information, including announcements about its RISE strategy and related 2028 financial targets for revenue growth, trading profit, free cash flow and post-tax return on invested capital. Other 6-Ks detail portfolio rationalisation plans, guidance for upcoming financial years, and information on Capital Markets Day events where management presents strategic and product updates.
Filings also include voting rights and capital disclosures, setting out the total issued share capital, treasury shares and the number of voting rights that shareholders should use when assessing notification thresholds under applicable transparency rules. Separate TR-1 notifications, reproduced within 6-Ks, report major holdings changes by institutional investors such as BlackRock, Inc., including the percentage of voting rights attached to shares and through financial instruments.
Additional 6-K reports provide Market Abuse Regulation-compliant notifications of transactions by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These cover purchases of ordinary shares and American Depositary Shares, participation in dividend reinvestment and employee stock purchase plans, and vesting of restricted share awards, giving a view of insider dealing activity around SNN securities.
Investors can also find transaction-related disclosures, such as the acquisition of Integrity Orthopaedics and its Tendon Seam™ rotator cuff repair technology, including headline deal terms, strategic rationale within the Sports Medicine portfolio and comments from management. By combining real-time EDGAR updates with AI-powered summaries, this page helps users navigate Smith & Nephew’s 6-Ks, understand the implications of voting rights and insider transactions, and quickly grasp the strategic content of narrative announcements without reading every paragraph in full.
Smith & Nephew plc reported its issued share capital as at 30 September 2025. The company has 877,724,845 ordinary shares of US20¢ each, of which 24,102,908 are held in treasury. That leaves 853,621,937 ordinary shares with voting rights, and the company states this figure should be used as the denominator for shareholder disclosure requirements under the FCA's Disclosure Guidance and Transparency Rules. The notice is signed by the Company Secretary and provides a contact for the Deputy Company Secretary.
Smith+Nephew announced that Chief Financial Officer John Rogers will relocate to the United States and be employed under a U.S. contract effective 29 September 2025. The move is intended to strengthen executive leadership and oversight in the U.S., which generates over half of Group revenue. His base salary will move from
Smith & Nephew plc filed a report disclosing a share transaction by a senior manager under UK Market Abuse Regulation. Vasant Padmanabhan, President Research & Development ENT and classified as a person discharging managerial responsibilities, carried out a sale of 17,643 Smith & Nephew ordinary shares on 9 September 2025. The shares have a nominal value of USD 0.20 each, and the transaction price recorded in the disclosure was £14.25 per share. The grant was noted as taking place outside a trading venue, and the disclosure was signed on behalf of the company by the Company Secretary.
Smith & Nephew plc filed a Form 6-K detailing a management share transaction under UK Market Abuse Regulation. The filing reports that Chief Compliance Officer Alison Parkes, classified as a PDMR, sold 5,800 ordinary shares of Smith & Nephew plc on 8 September 2025.
The ordinary shares, with a nominal value of USD 0.20 each, were sold on the London Stock Exchange (XLON) at a price of £14.113605 per share in a single transaction. The disclosure is formally signed on behalf of Smith & Nephew plc by Company Secretary Helen Barraclough.
Smith & Nephew plc reports its total issued share capital as at 31 August 2025 is 877,718,356 ordinary shares of US20¢ each, which includes 6,748,465 ordinary shares held in treasury. After excluding treasury shares, the number of ordinary shares with voting rights is 870,969,891. Shareholders should use this voting-share figure as the denominator for determining notification thresholds under the FCA's Disclosure Guidance and Transparency Rules.
Smith & Nephew plc announced awards under its Global Share Plan 2020 granted on 27 August 2025 to Ajay Dhankhar. The awards are based on the London Stock Exchange closing share price of £13.48 measured between 6 and 19 August 2025. Performance Share awards include 40,005 shares at target vesting (vesting 8 March 2027, performance period 1 Jan 2024–31 Dec 2027) and 87,370 shares shown at maximum vesting (vesting 27 August 2028, performance period 1 Jan 2025–31 Dec 2028). Restricted Share awards vest in three equal tranches on 27 August 2026, 27 August 2027 and 27 August 2028, each subject to continued employment and satisfactory performance.
Smith & Nephew announced the appointment of Dr Garheng Kong as an independent Non-Executive Director and member of the Audit Committee, effective 1 September 2025. Dr Kong is managing partner and co-founder of HealthQuest Capital and holds non-executive roles including lead independent director of LabCorp and directorships at Xeris Biopharma, Lunit and IKS Health. The company notes his prior roles at Sofinnova Investments and several medtech and biopharma boards. Smith & Nephew describes itself as a global medical technology group with about 17,000 employees, operations in around 100 countries and annual sales of $5.8 billion in 2024. The filing states no UK Listing Rule disclosure obligations arise for this appointment.
Smith & Nephew plc disclosed routine share purchases made on 22 August 2025 under its Remuneration Policy to settle part of Non-Executive Directors' fees. The purchases were made net of tax and expenses and reported under the UK Market Abuse Regulation. Specific notifications include: Angie Risley acquiring 353 ordinary shares at £13.82 each; Jo Hallas acquiring 541 ordinary shares at £13.835323 each; and John Ma acquiring 202 ADRs at $37.249053 each. The announcement lists additional affected directors (Jez Maiden, Katarzyna Mazur-Hofsaess, Simon Lowth) as part of the group covered by the disclosure. The filing is a standard Form 6-K notice of insider transactions and was signed by the Company Secretary.
Smith & Nephew plc reported a notification of share purchases by a Non-Executive Director. On 20 August 2025 Sybella Stanley purchased 1,520 ordinary shares of US$0.20 each. The filing states the purchase was made in line with the company's Remuneration Policy to pay part of Non-Executive Directors' fees in shares, and that the shares were acquired net of tax and expenses. The report is a standard Section 16-style disclosure of transactions by persons discharging managerial responsibilities.
Smith & Nephew plc reported the partial vesting of awards under its Restricted Share Plan 2024. Awards granted on 16 August 2024 vest in three equal tranches on each anniversary, subject to a judgement by the Remuneration Committee. On 19 August 2025 the company received notifications that a Director had 43,839 ordinary shares vesting, of which 18,007 were sold to cover tax and 25,832 were retained. A Non-Executive Director had 2,800 shares vest. The notice discloses these transactions following the vesting event.